Clementia is a biopharmaceutical company dedicated to bringing effective new treatments to people who have none.
The company is developing its lead candidate palovarotene, a novel RARγ agonist, to treat Fibrodysplasia Ossificans Progressiva (FOP), Multiple Osteochondromas (MO), and other diseases.
We believe that palovarotene holds significant potential for individuals with debilitating bone and other diseases with high unmet medical need. Preliminary Phase 2 data in subjects with FOP mirrors the decrease in heterotopic ossification (HO) volume observed in lab studies in mouse models of FOP, and support the initiation of a confirmatory Phase 3 program. Palovarotene also inhibits the formation of osteochondromas (OCs) in mouse models of MO, supporting development in this indication.
Our name, Clementia, is derived from the Latin word for compassion or empathy – a concept that inspires everything we do.
Founded in 2011, Clementia is headquartered in Montreal, Canada with a U.S. subsidiary in Boston, MA.